Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

873653.pdf (3.06 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2022-02-02

Llicència de publicació

cc-by-nc-nd (c) Romecín, Paola Alejandra et al., 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/218503

A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.ymthe.2021.08.033

Resum

CD19-directed chimeric antigen receptor (CAR) T cells have yielded impressive response rates in refractory/relapse B cell acute lymphoblastic leukemia (B-ALL); however, most patients ultimately relapse due to poor CAR T cell persistence or resistance of either CD19+ or CD19- B-ALL clones. CD22 is a pan-B marker whose expression is maintained in both CD19+ and CD19- relapses. CD22-CAR T cells have been clinically used in B-ALL patients, although relapse also occurs. T cells engineered with a tandem CAR (Tan-CAR) containing in a single construct both CD19 and CD22 scFvs may be advantageous in achieving higher remission rates and/or preventing antigen loss. We have generated and functionally validated using cutting-edge assays a 4-1BB-based CD22/CD19 Tan-CAR using in-house-developed novel CD19 and CD22 scFvs. Tan-CAR-expressing T cells showed similar in vitro expansion to CD19-CAR T cells with no increase in tonic signaling. CRISPR-Cas9-edited B-ALL cells confirmed the bispecificity of the Tan-CAR. Tan-CAR was as efficient as CD19-CAR in vitro and in vivo using B-ALL cell lines, patient samples, and patient-derived xenografts (PDXs). Strikingly, the robust antileukemic activity of the Tan-CAR was slightly more effective in controlling the disease in long-term follow-up PDX models. This Tan-CAR construct warrants a clinical appraisal to test whether simultaneous targeting of CD19 and CD22 enhances leukemia eradication and reduces/delays relapse rates and antigen loss.

Matèries

Limfòcits, Antígens, Immunoteràpia

Matèries (anglès)

Lymphocytes, Antigens, Immunotheraphy

Citació

Col·leccions

Articles publicats en revistes (Ciències Fisiològiques)

Citació

ROMECÍN, Paola Alejandra, et al. A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL. Molecular Therapy. 2022. Vol. 30, num. 2, pags. 550-563. ISSN 1525-0016. [consulted: 14 of August of 2026]. Available at: https://hdl.handle.net/2445/218503

Exportar metadades

JSON - METS

Compartir registre